Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic disease with unknown etiology and poor prognosis. Little is known about the epidemiology of this disease; most of the studies are limited by small and restricted cohort studies. We aim to investigate the epidemiology of IPF in the Italian primary care setting using the Health Search Database (HSD) between January 2002 and June 2017. In an attempt to define cases of IPF we adopted iterative combinations of International Classification of Diseases Ninth Revision (ICD-9-CM) and other clinical investigations according to three different operational Algorithms. Incidence and prevalence rate, according to the three Algorithms defining IPF, were calculated and the association with candidate determinants [sex, age, gastro-esophageal reflux (GERD) and smoking status] was evaluated. We identified 1,104,307 eligible patients. The prevalence rate of IPF varies between 2.6 to 24.3 per 100.000 person-year, using algorithm 1 and from 0.8 to 7 using algorithm 3. The incidence rate of IPF varies between 1.25 and 3.77 per 100.000 person-years, using algorithm 1 and from 0.10 to 1.61 using algorithm 3. The mean adjusted incidence rate ratio of IPF, using algorithm 1, is 2.33 (95% CI 2.11–2.57) per 100.000 person-years. Over the study years, the trend of prevalence was statistically significantly increasing while the incidence rate started to increase in the last 3 years. The analyses on candidate determinants showed that patients aged 61 years or older, those suffering from GERD, and former smokers were statistically significantly at greater risk of incurring IPF. To our knowledge, this is one of the first European IPF epidemiological studies conducted in primary care. The increase of the incidence rates is likely due to a growing awareness for IPF among General Practitioners, while the increase of prevalence rates may be due to an increase of survival, a result of recent advances in the diagnosis, management and therapies for the disease.
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11739-019-02195-0/MediaObjects/11739_2019_2195_Fig1_HTML.png)
Similar content being viewed by others
References
Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824
Caminati A, Harari S (2010) IPF: new insight in diagnosis and prognosis. Respir Med 104(Suppl 1):S2–10
Luppi F, Cerri S, Taddei S, Ferrara G, Cottin V et al (2015) Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Intern Emerg Med 10(4):401–411
Fernández Pérez ER, Daniels CE, Schroeder DR et al (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis a population-based study. Chest 137(1):129–137
Barbagli E, Di Masi M, Perruzza M et al (2009) The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis. Intern Emerg Med 4(6):535–537
Ryu JH, Moua T, Daniels CE et al (2014) Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc 89(8):1130–1142
Wolters PJ, Collard HR, Jones KD (2014) Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 9:157–179
Conti S, Harari S, Caminati A et al (2018) The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy. Eur Respir J 51(1)
Johannson KA, Strâmbu I, Ravaglia C et al (2017) Antiacid therapy in idiopathic pulmonary fibrosis: more questions that answers. Lancet Respir Med 5(7):591–598
Dipaola F, Galli A, Selmi C, Furlan R (2015) Efficacy of medical therapy in a case of idiopathic pulmonary fibrosis due to gastroesophageal reflux disease. Intern Emerg Med 10(4):401–411
Armanios MY, Chen JJ-L, Cogan JD et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317–1326.
Liu T, Ullenbruch M, Choi YY et al (2013) Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol 49(2):260–268
Lederer D, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 378(19):1811–1823
Coultas DB, Zumwalt RE, Black WC et al (1994) The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150(4):967–972
Raghu G, Jardin MR, Myers J et al (2018) Diagnosis of idiopathic pulmonary fibrosis an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68
Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46(3):795–806
Caminati A, Madotto F, Cesana G, Conti S, Harari S (2015) Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 24:436–444
Gribbin J, Hubbard R, Le Jeune I, Smith CJ, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980–985
Navaratnam V, Fleming KM, West J et al (2011) The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 66:462–467
Strongman H, Kausar I, Maher TM (2018) Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther 35:724–736
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174(7):810–816
Hopkins RV, Burke N, Fell C, Dion G, Kolb M (2016) Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 48:187–19520
Ntsuizaka M, Chiba H, Kuronuma K et al (2014) Epidemiologic survey of japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190:773–779
Harari S, Madotto F, Caminati A, Conti S, Cesana G (2016) Epidemiology of idiopathic pulmonary fibrosis in northern Italy. PLoS ONE 11(2):e0147072
Breslow NE (1996) Statistics in epidemiology: the case-control study. J Am Stat Assoc 91(433):14–28
Cricelli C, Mazzaglia G, Samani F et al (2003) Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 25(3):254–257
Guglielmi V, Bellia A, Bianchini E, et al. Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care. Endocrine. 2017:1–8.
Filippi A, Vanuzzo D, Bignamini AA, Mizzaglia C, Cricelli C, Catapano AL (2005) The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J 6(4):311–314
Nurmi H, Selander T, Purokivi M, Kaarteenaho R (2017) Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res 18(1):160
Lee JS, Collard HR, Raghu G et al (2010) Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 123:304–311
Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D (2012) Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 21:355–361
Kaunisto J, Salomaa ER, Hodgson U et al (2013) Idiopathic pulmonary fibrosis—a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med 13:53
Raghu G, Chen SY, Yeh WS et al (2014) Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–2011. Lancet Respir Med 2(7):566–572
Ferrara G, Arnheim-Dahlstrom L, Bartley K et al (2019) Epidemiology of pulmonary fibrosis: a cohort study using healthcare data in Sweden. Pulm Ther. https://doi.org/10.1007/s41030-019-0087-9
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Sergio Harari has relationship with drug company Roche, Actelion and Boehringer Ingelheim. In addition to being investigator in trials involving these companies, relationships include lectures and membership of scientific advisory boards and grant for research. Michele Davì is a medical manager, unit Rare Diseases, at Roche S.p.A. Alessandra Ghirardini is a medical unit head, unit Rare Diseases, at Roche S.p.A. Valeria Lovato is a country study manager at Roche S.p.A. Francesco Lapi and Cricelli Claudio has received research grants from Roche for research activities. Alice Biffi and Antonella Caminati have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
For this type of study formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Harari, S., Davì, M., Biffi, A. et al. Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care. Intern Emerg Med 15, 437–445 (2020). https://doi.org/10.1007/s11739-019-02195-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-019-02195-0